Читать книгу Recent Advances in Dialysis Therapy in Japan - Группа авторов - Страница 89

Liraglutide and lixisenatide should be carefully administered to patients with impaired kidney function, including dialysis patients. Exenatide is contraindicated for dialysis patients. Extended-release exenatide and long-acting dulaglutide are GLP-1 receptor agonists administered as weekly subcutaneous injections. Extended-release exenatide is contraindicated in dialysis patients. On the other hand, dulaglutide can be administered at the same dose to dialysis patients as to those with normal kidney function, but careful follow-up is necessary because there is insufficient experience.

Table 1. Metabolic pathway, dialyzability, and dose of oral hypoglycemic agents